STOCK INFORMATION
WEB CONFERENCES
Media
Watch AB Science’s web conference replays.
Listing information
Share priceEuronext
EligibilityPEA YesSRD Yes
ISIN codeFR0010557264
ICB classification
4000 IndustryHealth Care
4500 SupSectorHealth Care
4570 SectorPharmaceuticals & Biotechnology
4577 SubSectorPharmaceuticals
Discover AB SCIENCE’s strengths, programmes and prospects.
AB SCIENCE’s strengths
A differentiated position based on unmet medical need, therapeutic innovation and control of intellectual property.
High unmet medical need and strong market potential
- The diseases in development all address high unmet medical needs (Alzheimer’s disease, amyotrophic lateral sclerosis and acute myeloid leukaemia)
- The development programmes combine diseases with strong market potential and orphan diseases
Unique mechanism of action
- The lead compound, masitinib, is a kinase inhibitor that selectively targets the immune system through mast cells and macrophages / microglia
- The new compound, AB8939, is a next-generation synthetic microtubule destabiliser capable of overcoming multidrug resistance
Secure intellectual property
- Intellectual property 100% owned by AB SCIENCE
FINANCIAL DOCUMENTS
Documents for investors
Find AB SCIENCE’s latest financial reports.
30 June 2026
Half-year report of the AB SCIENCE group.
Financial year 2025
Annual report of the AB SCIENCE group as at 31 December 2025.